Skip to main content

AI-Supported Mammography Screen Reading Seems Promising

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 7, 2023 -- Cancer detection is similar for artificial intelligence (AI)-supported mammography screen reading compared with standard double reading, according to a study published online Aug. 1 in The Lancet Oncology.

Kristina Lång, Ph.D., from Lund University in Sweden, and colleagues conducted a randomized, controlled, population-based trial involving women aged 40 to 80 years who were eligible for mammography screening at four sites in Sweden. Participants were randomly assigned to AI-supported screening or standard double reading without AI. The AI system provided an examination-based malignancy risk score, which was used to triage screening examinations to single-reading or double-reading risk scores. This study reported the prespecified clinical safety analysis for 80,033 women randomly assigned to AI-supported screening (40,003 women) or double reading without AI (40,030 women).

The researchers found that cancer detection rates were 6.1 and 5.1 per 1,000 screened participants in the intervention and control groups, respectively; the detection rate in the intervention group was above the lowest acceptable limit for safety. Recall rates were 2.2 and 2.0 percent in the intervention and control groups, respectively. In both groups, the false-positive rate was 1.5 percent. The positive predictive value of recall was 28.3 and 24.8 percent in the intervention and control groups, respectively. In the intervention group, 75 and 25 percent of cancers detected were invasive and in situ, respectively, compared with 81 and 19 percent, respectively, in the control group. Using AI, the screen-reading workload was reduced by 44.3 percent.

"The greatest potential of AI right now is that it could allow radiologists to be less burdened by the excessive amount of reading," Lång said in a statement.

One author disclosed ties to the pharmaceutical and medical technology industries.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted August 2023

Read this next

NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians

FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...

Acupuncture Reduces Endocrine Symptoms, Hot Flashes in Breast Cancer

MONDAY, June 24, 2024 -- A 10-week acupuncture intervention significant reduces endocrine symptoms and hot flashes among women with breast cancer receiving endocrine therapy (ET)...

Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants

FRIDAY, June 21, 2024 -- The cumulative risk for advanced gastric cancer varies from 6.5 to 10.3 percent for carriers of germline CDH1 pathogenic/likely pathogenic (P/LP)...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.